Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (401-410 of 512) with videos related to

Pageof 52
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyBenjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.
The Journal of Pathology|September 27, 2024
DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymomaMehdi Latiri, Mohamed Belhocine, Charlotte Smith, et al.
Cancer Research|November 13, 2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted AgentsAntoine Azan, Peter J Caspers, Tom C Bakker Schut, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerEng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.
Cancer Discovery|March 2, 2023
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic CancerYoann Pradat, Julien Viot, Andrey A Yurchenko, et al.
Nature Medicine|June 5, 2020
Author Correction: Caring for patients with cancer in the COVID-19 eraJoris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.
Cancer Discovery|June 28, 2023
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial CancerFrancesco Facchinetti, Antoine Hollebecque, Floriane Braye, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC NetworksSarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Translational Lung Cancer Research|August 13, 2025
Upfront osimertinib and as sequential therapy in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile studyEdouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, et al.
Pageof 52

Showing results (401-410 of 512) with videos related to

Sort By:
Pageof 52
European Journal of Cancer (Oxford, England : 1990)|April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE studyAlexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2015
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II StudyBenjamin Besse, Sylvestre Le Moulec, Julien Mazières, et al.
The Journal of Pathology|September 27, 2024
DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymomaMehdi Latiri, Mohamed Belhocine, Charlotte Smith, et al.
Cancer Research|November 13, 2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted AgentsAntoine Azan, Peter J Caspers, Tom C Bakker Schut, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerEng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.
Cancer Discovery|March 2, 2023
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic CancerYoann Pradat, Julien Viot, Andrey A Yurchenko, et al.
Nature Medicine|June 5, 2020
Author Correction: Caring for patients with cancer in the COVID-19 eraJoris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.
Cancer Discovery|June 28, 2023
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial CancerFrancesco Facchinetti, Antoine Hollebecque, Floriane Braye, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC NetworksSarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Translational Lung Cancer Research|August 13, 2025
Upfront osimertinib and as sequential therapy in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile studyEdouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, et al.
Pageof 52